Drug intelligence / Profile preview

VeriClenz

Development stage: Preclinical
Lead developer: Armis Biopharma
Modality: Small Molecules
Administration: Topical

Overview

VeriClenz is a topical antimicrobial and disinfectant solution developed by Armis Biopharma, utilizing the proprietary Veriox® technology platform. This platform is characterized by a peracid-based oxidative chemistry that provides broad-spectrum activity against bacteria, viruses, and fungi. VeriClenz is intended for wound care and disinfection applications, acting through a physical-chemical mechanism that disrupts microbial cell walls and proteins, thereby minimizing the risk of antimicrobial resistance. It is classified as a medical device and is currently positioned within the company's product development pipeline, distinguishing it from the company's commercially available products like VeriCyn and ArmiClenz.

Brand names: VeriClenz
Other names: VeriClenz™

Beyond the preview

Go deeper on VeriClenz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VeriClenz.

Explore the full profile